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OBJECTIVES: To investigate patterns of statin use in an Italian
Local Health Unit (LHU) between 2002 and 2006. METHODS:
Prescription records from Pieve di Soligo (Treviso) LHU were
analysed during ﬁve years. Data of patients having at least one
statin prescription were retrieved. Each prescription was linked
to relevant patient code and identiﬁed by issue date, product
name, package description, packages/prescription number and
retail price. Patient’s information consisted of gender and birth
date. RESULTS: In total, 218,000 residents (4.7% of Veneto
Region) have NHS coverage through this LHU. Statin prescrip-
tion concerned 8,107 patients in 2002 and 9,872 in 2006.
Simvastatin was always the most commonly prescribed active
principle accounting for 51% of prescription in 2002 (4 available
molecules) and 37.7% in 2006 (6 available molecules). Overall
statins utilization steadily increased from 50,212 prescriptions
in 2002 to 61,917 in 2004. In 2004, a revision of prescription
limitations caused a reduction in the number of patients eligible
to free-of-charge medications, with a fall of total prescription to
47,719 and 46,118 in 2005 and 2006 respectively. Expenditure
on statins increased from about €2.02 Mio in 2002 to €3.21 Mio
approx. in 2004, showing a slight reduction to €3.09 Mio in
2006. Average yearly per-patient expenditure showed limited
variations (€249 in 2002, €298 in 2004 and €313 in 2006) due to
changes in pack size, product mix and owing to repeated drugs’
price cut. Median patient/prescription number and median
number of packages/prescription were stable throughout the
period. CONCLUSION: Statin prescription increase observed in
early 2000s seems not to be directly inﬂuenced by the availability
of active principles. Introduction of new reimbursement criteria
markedly reduced prescription of lipid-lowering drugs at NHS
charge. Indicators aiming at assessing speciﬁc appropriateness of
statin prescriptions should be developed and periodic audits
implemented.
PCV57
UTILISATION OF DRUGS FORTREATMENT OF
CARDIOVASCULAR DISEASE WITHIN SLOVAKIA
Tesar T1, Foltán V1,Tomek D2, Ilavska A3
1Comenius University, Bratislava, Slovak Republic, 2Health Insurance
Fund Apollo, Bratislava, Slovak Republic, 3Railway Hospital, Bratislava,
Slovak Republic
OBJECTIVES: The aim of this study was to collect comparable
and reliable data on therapy of cardiovascular disease in Slo-
vakia during the period 1997–2006. The special interest was
paid to the utilisation of antihypertensive medication.
METHODS: For 1997–2006, the data about consumption of
drugs for treatment of cardiovascular disease were collected, in
accordance with the Anatomic Therapeutic Chemical classiﬁca-
tion (ATC: C01–C10) and Deﬁned Daily Dose (DDD) measure-
ment unit. Data of wholesalers, who are legally obliged provide
this information to the Slovak Institute for Drug Control, was
used for the analysis. RESULTS: A signiﬁcant increase in the
consumption of drugs for cardiovascular disease (in 1997
(238.06), in 2001 (329.27) and in 2006 (450.08) in term of
DDD/1000/day can be seen from this analysis. The results show
that the consumption (in term of DDD/1000/day) of ß-blockers
was (in 1997 (28.88), in 2001 (36.36) and in 2006 (45.13),
ACE inhibitors (in 1997 (32.68), in 2001 (70.51) and in 2006
(115.52), Ca-blockers (in 1997 (29.60), in 2001 (46.09) and in
2006 (71.09), diuretics (in 1997 (23.88), in 2001 (30.16) and
in 2006 (38.23), peripheral vasodilators (in 1997 (19.10), in
2001 (21.36) and in 2006 (14.58), vasoprotectives (in 1997
(34.99), in 2001 (37.10) and in 2006 (35.63), serum lipid
reducing agents (in 1997 (6.68), in 2001 (16.64) and in 2006
(48.08). In ﬁnancial terms, the consumption of b-blockers
in 1997 (5,596,000€) and 2006 (12,740,000€), ACE inhibitors
in 1997 (11,974,000€) and 2006 (42,671,000€), Ca-blockers in
1997 (8,690,000€) and 2006 (18,066,000€), diuretics
in 1997 (1,566,000€) and 2006 (3,711,000€) can be seen
from this study. CONCLUSION: Usage of generic drugs for
the treatment of cardiovascular disease brought about a dra-
matic increase in drug consumptions and the ﬁnancial expen-
ditures for health insurance funds have been remained under
control.
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OBJECTIVES: To understand the differences in reasons behind
physicians’ antihypertensive therapy choice both across the medi-
cation classes and geographies (Europe & US). METHODS:
CardioMonitor is a multi-purpose international initiative
conducted annually among primary-care physicians (PCPs) and
specialists to collect data on cardiovascular patients in the outpa-
tient setting. 2006 data from 5 major countries in Europe (EU5,
reported in aggregate) and the U.S for patients with hypertension
(HTN) diagnosis and/or antihypertensive use was included in the
analysis to evaluate the reasons for choice of three antihyperten-
sive classes (not mutually exclusive)—Angiotensin-II-Receptor
Blockers (ARB), Angiotensin-Converting Enzyme Inhibitors
(ACE) & Calcium Channel Blockers (CCB). RESULTS: In 2006,
17,220 & 3,530 patients from EU & US respectively satisﬁed
inclusion criteria, with distribution of 3 HTN medication classes
being (EU, US; % of patients)—ARB: 31%, 26%, ACE: 44%,
48%,CCB: 23%, 16%.Key reasons (notmutually exclusive) cited
by physicians for prescribing antihypertensives were (EU, US):
blood-pressure reduction/control (ARB: 98%, 96%, ACE: 92%,
93%, CCB: 89%, 94%), myocardial protection (ARB: 75%,
61%, ACE: 74%, 67%, CCB: 49%, 47%), simple dosing (ARB:
73%, 61%, ACE: 64%, 61%, CCB: 60%, 59%), achieve good
patient compliance (ARB: 60%, 47%, ACE: 44%/ 41%, CCB:
44%, 40%), cerebrovascular protection (ARB: 54%, 51%, ACE:
45%, 47%, CCB: 37%, 39%), side-effect-minimization (ARB:
47%, 31%, ACE: 26%, 24%, CCB: 20%, 20%), heart-function
improvement (ARB: 33%, 25%, ACE: 44%, 30%, CCB:
18%, 13%), good tolerability (ARB: 46%, 42%, ACE: 40%,
35%, CCB: 35%, 32%), formulary/approved-list (ARB: 15%,
28%, ACE: 25%, 28%, CCB: 20%, 25%) and cost-minimization
(ARB: 1%, 6%, ACE: 10%, 18%, CCB: 6%, 9%). CONCLU-
SION: Cardiovascular conditions, product attributes and patient/
health-system issues appear to drive differences in the reasons
behind medication choice both within the antihypertensive medi-
cation classes and between geographies (EU & US) which may
require close scrutiny.
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